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23
Obstructive kidney disease is a common complication in the clinic. Downregulation of 24 aquaporins (AQPs) in obstructed kidneys has been thought as a key factor leading to 25 the polyuria and impairment of urine-concentrating capability after the release of 26 kidney obstruction. The present study was to investigate the role of mitochondrial 27 complex-1 in modulating AQPs in obstructive nephropathy. Following 7-day unilateral 28 ureteral obstruction (UUO), AQP1, AQP2, AQP3, and V2 receptor were remarkably obstruction (8, 9, 22, 24) . One of the recognized reasons leading to the impairment of 50 renal concentration capability in obstructive nephropathy is the global reduction of 51 AQPs including AQP1, AQP2, and AQP3 in the kidney (11, 18, 20, 22, 37) . Generally, AQPs reduction in obstructed kidneys and improved the polyuria following the 59 obstruction release (4, 25) . In addition, Ang II was also reported to be attributable to 60 the downregulation of AQPs possibly via the stimulation of COX-2 in obstructive 61 kidney disease (10, 17, 18) . However, more intensive study is necessary for further 62 revealing the pathogenesis of AQPs dysregulation in this pathological process.
63
Recently, several reports from our and other groups demonstrated that 64 mitochondrial dysfunction contributes to the pathogenesis of CKDs including 65 obstructive kidney disease and 5/6nephrectomy animal model(3, 31). Mitochondria 66 play critical roles in regulating energy production, signaling transduction, cell 67 proliferation and cell cycle(5, 6). Impaired mitochondria elevated oxidative stress, 68 reduced ATP production, and initiated apoptotic process via the release of 69 mitochondrial DNA, cytochrome C et al (33, 34) . By now, the pathogenic role of 70 mitochondrial injury in mediating the pathological response in chronic and acute 71 kidney diseases has been widely recognized (12, 29, 31, 32, 36, 39) . However,
72
whether mitochondrial dysfunction play a role in regulating AQPs in a CKD model of 73 UUO is still unknown.
74
In the present study, employing a pharmacological strategy, we defined: 1) 
Methods
80
Animals
81
The C57BL/6J mice were originally purchased from Jackson lab, which was propagated 82 at the Nanjing Medical University. In our studies, 3-to 4-month-old male mice were 83 used. All mice were maintained under a 12:12 hour light-dark cycle. This study was 84 approved by the Nanjing Medical University Institutional Animal Care and Use
85
Committee.
86
UUO mouse model and rotenone treatment
87
Unilateral ureter obstruction was established as described previously (30, 31 was administered to the UUO mice at a dose of 10mg/kg by osmotic minipumps for 48h.
94
After two or seven days of UUO with rotenone or SC-51322 treatment, mice were 95 anesthetized with an intraperitoneal injection of a ketamine/xylazine/atropine mixture,
96
and the kidneys and blood were collected for the analysis.
97
Immunoblotting
98
Kidney tissues were lysed using the protein lysis buffer containing 50 mM Tris, 150 mM 99 NaCl, 10 mM EDTA, 1% Triton X-100, 200 mM sodium fluoride, and 4 mM sodium 100 orthovanadate, as a protease inhibitor (pH 7.5) and protein concentration was 
qRT-PCR
124
Total RNA isolation and reverse transcription were finished as previously described(39).
125
Oligonucleotides were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) 126 and the sequences are shown in the 
Results
142
Kidney obstruction led to Mitochondrial Abnormality.
143
Following 7 days UUO, we evaluated the mitochondrial status via the examination of 144 mitochondrial DNA copy number (mtDNA), mitochondrial transcription factor (mTFAM),
145
and mitochondria-encoded NADH dehydrogenase 1 (mtNd1) using qRT-PCR. As 146 expected, 7-day ureteral obstruction resulted in striking reduction of mtDNA (Fig.1A) , 147 mTFAM (Fig. 1B) , and mtNd1 (Fig. 1C) , indicating that mitochondrial abnormality occurs 148 in obstructed kidneys.
149
Effects of rotenone on AQPs expression in obstructed kidneys.
150
Following 7-day UUO, the expression of AQP1 was dramatically decreased in the 151 obstructed kidneys as compared to sham controls ( Fig. 2A & B) . Strikingly, in the obstructed kidneys, which was further confirmed by immunohistochemistry ( Fig.   159 4). Similarly, vasopressin receptor 2 (V2) also showed a significant reduction in 160 obstructed kidneys and was completely reversed by rotenone administration (Fig. 5) .
161
This data suggested that V2 receptor may play a role in mediating AQP2 regulation in 162 this experimental setting at least to some extent. 
172
Effects of rotenone on AQPs in kidneys after 48h obstruction.
173
Then we further examined rotenone effects on AQPs' regulation in kidneys after 48h 
179
Effects of rotenone on AQPs in non-obstructed kidneys.
180
To evaluate the effects of rotenone on the expression of AQPs in non-obstructed 181 kidneys, mice were subjected to the jelly diet with or without rotenone for 7days. Then (Fig. 11A-F ). However, rotenone had no effect on the 199 regulation of all these enzymes (Fig. 11A-F) . We further confirmed protein expression of 200 COX-2 via Western blotting and found a similar pattern as its mRNA level (Fig. 12A&B ).
201
Moreover, the induction of kidney PGE2 content was also not affected by rotenone (Fig.   202   12C ). These data highly indicated that rotenone treatment played no role in regulating 203 COX/PGES/PGE2 cascade in this experimental setting.
204
Effects of rotenone on PGE2 receptors in obstructed kidneys.
205
PGE2 functions through four receptors including EP1, EP2, EP3, and EP4. Although 206 COX-/PGES/PGE2 cascade was not altered by rotenone, we can't rule out a possible 207 role of rotenone in regulating PGE2 receptors which finally decide PGE2 action.
208
Interestingly, EP2 and EP4 but not EP1 and EP3 were upregulated in obstructive 209 kidneys as determined by qRT-PCR (Fig 13A-D) . Importantly, rotenone strikingly 210 suppressed EP1 and EP4 but not EP2 and EP3 receptors (Fig. 13A-D) . EP1 regulation 211 was further confirmed by Western blotting (Fig. 14A&B) . These results suggested that 212 suppression of EP1 and/or EP4 receptors possibly played a role in protecting against
213
AQPs downregulation in rotenone-treated obstructed kidneys.
214
Antagonism of EP1 receptor did not affect AQPs' reduction in obstructed kidneys.
215
In consideration of the diuretic role of EP1, we treated the UUO mice with EP1 216 antagonist SC-51322. Unexpectedly, we did not find its effect on the downregulated 217 AQPs in UUO kidneys as determined by qRT-PCR (Fig. 15A-C As a common clinical complication, obstructive nephropathy leads to a remarkable 223 downregulation of AQPs (11, 18, 22, 37) . The release of kidney obstruction is followed 224 by polyuria, which could lead to severe disorders of fluid metabolism. In the past years, Several studies reported that mitochondrial abnormality is an obvious phenomenon 230 in obstructed kidneys (12, 31, 36, 39) . In this study, we also confirmed this phenomenon 231 as shown by the significant reduction of mtDNA copy number, mTFAM, and mtNd1. in obstructive nephropathy at least to some extent.
250
In order to examine the potential mechanism involved in the rotenone effect on the 
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